160 related articles for article (PubMed ID: 36049109)
21. Preparation and Imaging Investigation of Dual-targeted C
Du J; Li XY; Hu H; Xu L; Yang SP; Li FH
Sci Rep; 2018 Mar; 8(1):3887. PubMed ID: 29497045
[TBL] [Abstract][Full Text] [Related]
22. Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit.
Wang Y; Abenojar EC; Wang J; de Leon AC; Tavri S; Wang X; Gopalakrishnan R; Walker E; MacLennan GT; Giles A; Czarnota GJ; Basilion JP; Exner AA
Prostate; 2022 May; 82(6):695-705. PubMed ID: 35167141
[TBL] [Abstract][Full Text] [Related]
23. Preparation Of Nanobubbles Modified With A Small-Molecule CXCR4 Antagonist For Targeted Drug Delivery To Tumors And Enhanced Ultrasound Molecular Imaging.
Peng Y; Zhu L; Wang L; Liu Y; Fang K; Lan M; Shen D; Liu D; Yu Z; Guo Y
Int J Nanomedicine; 2019; 14():9139-9157. PubMed ID: 32063704
[TBL] [Abstract][Full Text] [Related]
24. Ultrasound-mediated drug-free theranostics for treatment of prostate cancer.
Perera RH; Berg FM; Abenojar EC; Nittayacharn P; Kim Y; Wang X; Basilion JP; Exner A
Bioact Mater; 2024 May; 35():45-55. PubMed ID: 38304914
[TBL] [Abstract][Full Text] [Related]
25. The unique second wave phenomenon in contrast enhanced ultrasound imaging with nanobubbles.
Chen C; Perera R; Kolios MC; Wijkstra H; Exner AA; Mischi M; Turco S
Sci Rep; 2022 Aug; 12(1):13619. PubMed ID: 35948582
[TBL] [Abstract][Full Text] [Related]
26. Production and characterization of a novel long-acting Herceptin-targeted nanobubble contrast agent specific for Her-2-positive breast cancers.
Jiang Q; Hao S; Xiao X; Yao J; Ou B; Zhao Z; Liu F; Pan X; Luo B; Zhi H
Breast Cancer; 2016 May; 23(3):445-55. PubMed ID: 25691133
[TBL] [Abstract][Full Text] [Related]
27. Ultrasonic Nanobubbles Carrying Anti-PSMA Nanobody: Construction and Application in Prostate Cancer-Targeted Imaging.
Fan X; Wang L; Guo Y; Tu Z; Li L; Tong H; Xu Y; Li R; Fang K
PLoS One; 2015; 10(6):e0127419. PubMed ID: 26111008
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate-loaded PLGA nanobubbles for ultrasound imaging and Synergistic Targeted therapy of residual tumor during HIFU ablation.
Zhang X; Zheng Y; Wang Z; Huang S; Chen Y; Jiang W; Zhang H; Ding M; Li Q; Xiao X; Luo X; Wang Z; Qi H
Biomaterials; 2014 Jun; 35(19):5148-61. PubMed ID: 24680663
[TBL] [Abstract][Full Text] [Related]
29. Improving ovarian cancer imaging with LHRH-NBs: an experimental study.
Li W; Zhang L; Zhu Y; Zhang J; Shen L; Huang S; Fang S
Arch Gynecol Obstet; 2016 Sep; 294(3):631-8. PubMed ID: 27075493
[TBL] [Abstract][Full Text] [Related]
30. Ultrasound molecular imaging of ovarian cancer with CA-125 targeted nanobubble contrast agents.
Gao Y; Hernandez C; Yuan HX; Lilly J; Kota P; Zhou H; Wu H; Exner AA
Nanomedicine; 2017 Oct; 13(7):2159-2168. PubMed ID: 28603079
[TBL] [Abstract][Full Text] [Related]
31. Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1.
Apfelbeck M; Clevert DA; Ricke J; Stief C; Schlenker B
Clin Hemorheol Microcirc; 2018; 69(1-2):93-100. PubMed ID: 29660918
[TBL] [Abstract][Full Text] [Related]
32. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Wüstemann T; Barelli P; Kim D; Williams C; Zheng X; Bi C; Hu B; Warren JD; Hage DS; DiMagno SG; Babich JW
J Nucl Med; 2017 Sep; 58(9):1442-1449. PubMed ID: 28450562
[TBL] [Abstract][Full Text] [Related]
33. Multifunctional microbubbles and nanobubbles for photoacoustic imaging.
Xu RX
Contrast Media Mol Imaging; 2011; 6(5):401-11. PubMed ID: 22025340
[TBL] [Abstract][Full Text] [Related]
34. Quantitative analysis of in-vivo microbubble distribution in the human brain.
Prada F; Gennari AG; Linville IM; Mutersbaugh ME; Chen Z; Sheybani N; DiMeco F; Padilla F; Hossack JA
Sci Rep; 2021 Jun; 11(1):11797. PubMed ID: 34083642
[TBL] [Abstract][Full Text] [Related]
35. Quantitative ultrasound molecular imaging by modeling the binding kinetics of targeted contrast agent.
Turco S; Tardy I; Frinking P; Wijkstra H; Mischi M
Phys Med Biol; 2017 Mar; 62(6):2449-2464. PubMed ID: 28240217
[TBL] [Abstract][Full Text] [Related]
36. FN3 linked nanobubbles as a targeted contrast agent for US imaging of cancer-associated human PD-L1.
Kumar US; Natarajan A; Massoud TF; Paulmurugan R
J Control Release; 2022 Jun; 346():317-327. PubMed ID: 35469983
[TBL] [Abstract][Full Text] [Related]
37. Preparation of multifunctional nanobubbles and their application in bimodal imaging and targeted combination therapy of early pancreatic cancer.
Yang H; Zhao P; Zhou Y; Li Q; Cai W; Zhao Z; Shen J; Yao K; Duan Y
Sci Rep; 2021 Mar; 11(1):6254. PubMed ID: 33737559
[TBL] [Abstract][Full Text] [Related]
38. The therapeutic effect in gliomas of nanobubbles carrying siRNA combined with ultrasound-targeted destruction.
Cai W; Lv W; Feng Y; Yang H; Zhang Y; Yang G; Duan Y; Wang J
Int J Nanomedicine; 2018; 13():6791-6807. PubMed ID: 30425489
[TBL] [Abstract][Full Text] [Related]
39. Time-intensity-curve Analysis and Tumor Extravasation of Nanobubble Ultrasound Contrast Agents.
Wu H; Abenojar EC; Perera R; De Leon AC; An T; Exner AA
Ultrasound Med Biol; 2019 Sep; 45(9):2502-2514. PubMed ID: 31248638
[TBL] [Abstract][Full Text] [Related]
40. Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry.
Zlitni A; Yin M; Janzen N; Chatterjee S; Lisok A; Gabrielson KL; Nimmagadda S; Pomper MG; Foster FS; Valliant JF
PLoS One; 2017; 12(5):e0176958. PubMed ID: 28472168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
